HHS Price Negotiations For Part D Not A Problem For Medco, CEO Snow Says
Medco is not worried about the possibility that the federal government may step in to negotiate drug prices for the Medicare Part D program, according to CEO David Snow
You may also be interested in...
Medco is promoting a health care reform agenda that emphasizes cost savings from more efficient and effective care instead of focusing on who pays the bills
Sen. Baucus’ effort to simply strike the non-interference clause, rather than requiring negotiations, did not garner enough support to force a vote.
Elizabeth Fowler brings combination of Capitol Hill, White House and pharma industry experience to the role of director of the Center for Medicare and Medicaid Innovation.